ELIGARD (Mundipharma Pty Ltd)
Product name
ELIGARD
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
Leuprorelin acetate
Registration type
EOI
Indication
ELIGARD 45mg 6 month is now also indicated for the treatment of children 2 years of age and older with central precocious puberty (CPP).